LL-37: Side Effects & Safety

LL-37 is the C-terminal 37-amino-acid peptide of human cathelicidin antimicrobial protein (hCAP18). It is an endogenous antimicrobial peptide produced by neutrophils, epithelial cells, and several other cell types — your body makes it every day.^[1] The critical safety story for LL-37 is dose-dependence: at physiological and modestly supraphysiological concentrations it is immunomodulatory and antimicrobial; at substantially elevated concentrations it becomes pro-inflammatory and is implicated in driving several autoimmune diseases.^[2]

LL-37 is not on the agenda for the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list meeting (the seven peptides under review are BPC-157, TB-500, KPV, MOTS-c, DSIP/Emideltide, Epitalon, and Semax). LL-37 is not FDA-approved. See our legal status guide for current US regulatory context.

Effect	Frequency	Mechanism
Injection-site reaction (redness, warmth, soreness)	Common	Local immune activation — more pronounced than other peptides because LL-37 is itself an immune-stimulating molecule
Localized swelling / induration	Common at higher doses	Local inflammatory cascade
Transient fatigue	Reported	Cytokine release; similar to mild flu-like response
Low-grade fever / chills	Rare	Higher doses; cytokine release
Worsening of pre-existing skin condition	Reported	Particularly psoriasis (see autoimmune section)
Allergic / hypersensitivity reaction	Rare	Discontinue immediately

The published clinical literature on exogenous LL-37 administration in humans is small — most safety data comes from observational studies of endogenous LL-37 levels in disease and from in vitro / animal research. The injection-site reactions and mild flu-like effects are the most consistently reported observations from real-world peptide use.

This is the most clinically important section. Elevated LL-37 is mechanistically implicated in several autoimmune diseases:

• Psoriasis: LL-37 binds self-DNA released by keratinocytes and the LL-37–DNA complex activates plasmacytoid dendritic cells via TLR9, driving interferon-alpha production and the autoimmune cascade. LL-37 is a recognized autoantigen in psoriasis.^[3] Exogenous LL-37 administration would plausibly exacerbate active psoriasis and is contraindicated.
• Systemic lupus erythematosus (SLE): elevated LL-37 has been documented in SLE and is implicated in NETosis-related autoimmunity. Anti-LL-37 autoantibodies have been described.
• Rosacea: abnormally processed LL-37 is implicated in the pathogenesis of rosacea inflammation.
• Rheumatoid arthritis: elevated LL-37 in synovial fluid; mechanistic role in inflammation.
• Atherosclerosis: LL-37 contributes to plaque inflammation; high circulating LL-37 has been linked to coronary disease in observational studies.

Implication for users: patients with psoriasis, lupus, rheumatoid arthritis, rosacea, severe atherosclerotic cardiovascular disease, or any active autoimmune inflammatory condition should not use exogenous LL-37. The mechanistic data is strong enough that this is more than a precautionary recommendation — exogenous LL-37 could plausibly worsen these conditions.

Most peptides have a relatively wide therapeutic window where slight overdosing produces no meaningful change in side-effect risk. LL-37 is different. The switch between immunomodulatory and pro-inflammatory activity is sharp and concentration-dependent. Practical implications:

• Buy from quality sources with verified peptide content. Unregulated supply where the actual content is uncertain creates real risk for LL-37.
• Use precise reconstitution math. See the peptide calculator.
• Start at the low end of any protocol and avoid the urge to "up the dose if it's not working" — at higher doses LL-37 may not just stop being beneficial, it may actively flip pro-inflammatory.
• Stop sooner rather than later if you experience prominent systemic inflammatory symptoms (fevers, chills, prolonged fatigue, joint or skin symptoms).

• Psoriasis, SLE, RA, rosacea or any active autoimmune inflammatory disease — strong contraindication.
• Severe atherosclerotic cardiovascular disease — relative contraindication given LL-37's role in plaque inflammation.
• Pregnancy and breastfeeding: no controlled data. Contraindicated.
• Active malignancy: mixed mechanistic data — LL-37 has both pro- and anti-tumorigenic effects across cancer types. Discuss with oncology.
• Severe chronic infections or immunocompromise: requires medical oversight; benefit/risk varies.
• Known hypersensitivity.

Drug interactions

• Immunosuppressants (methotrexate, biologics, cyclosporine): LL-37 opposes the therapeutic intent. Avoid combining.
• Other immune-stimulating peptides (thymosin alpha-1, etc.): theoretical additive immune activation; not recommended.
• NSAIDs: no specific interaction documented.

• Significant injection-site inflammation: reduce dose, rotate sites, evaluate technique. If recurrent, discontinue.
• Flu-like symptoms (fever, chills, fatigue): hold doses for 5–7 days. Resume at lower dose only if symptoms fully resolve. Discontinue if symptoms recur.
• New or worsening skin lesions: stop immediately and seek dermatology evaluation (LL-37 is mechanistically linked to psoriasis).
• New joint pain, rash, or systemic symptoms: evaluate for emerging autoimmunity. Stop and consult rheumatology if symptoms persist.
• Allergic reaction: discontinue immediately and seek emergency care.

See the LL-37 complete guide, dosage protocols, benefits and research, and the peptides for inflammation overview.